Company Filing History:
1 out of 14 
1 out of 1,289 
Years Active: 2024
Title: The Innovative Contributions of Melanie Schwalfenberg
Introduction
Melanie Schwalfenberg is a notable inventor based in Cork, Ireland. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target glucose transporters. Her work is crucial in addressing various metabolic and immunological diseases.
Latest Patents
Melanie holds a patent for her invention titled "Inhibitors of glucose transporters (GLUTs)." This invention relates to 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analogs, which serve as selective inhibitors of glucose transporters 1 and 3 (GLUTs 1 and 3). The patent outlines methods for preparing these compounds and their use as pharmaceutically active agents, especially for the treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis. Additionally, the invention includes pharmaceutical compositions comprising these compounds.
Career Highlights
Throughout her career, Melanie has worked with esteemed organizations such as Lead Discovery Center GmbH and Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Her experience in these institutions has allowed her to collaborate with leading scientists and contribute to groundbreaking research.
Collaborations
Some of her notable coworkers include Herbert Waldmann and Gunther Zischinsky. Their collaborative efforts have further advanced the research in the field of glucose transport inhibitors.
Conclusion
Melanie Schwalfenberg's innovative work in developing selective inhibitors of glucose transporters has the potential to significantly impact the treatment of various diseases. Her contributions to pharmaceutical sciences highlight the importance of research and collaboration in advancing medical therapies.